Human serum mast cell tryptase levels in elbow fractures or dislocations and its association with injury severity.
elbow
fracture
injury severity
mast cell
tryptase
Journal
Journal of orthopaedic research : official publication of the Orthopaedic Research Society
ISSN: 1554-527X
Titre abrégé: J Orthop Res
Pays: United States
ID NLM: 8404726
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
09
10
2019
revised:
07
01
2020
accepted:
19
02
2020
pubmed:
1
3
2020
medline:
15
12
2020
entrez:
1
3
2020
Statut:
ppublish
Résumé
Mast cells contain an abundance of tryptase, and preclinical models have shown elevated serum mast cell tryptase (SMCT) in the setting of posttraumatic joint contractures. Therefore, SMCT emerged as a potential biomarker to help recognize patients with more severe injuries and a higher likelihood of developing contractures. The objective of this study is to assess SMCT levels in participants with varying severity of elbow fractures and/or dislocations. A prospective cohort including 13 participants with more severe injuries that required an operation and 28 participants with less severe injuries managed nonoperatively were evaluated. A control group of eight individuals without elbow injuries was also evaluated. The SMCT levels were measured using an enzyme-linked immunosorbent assay kit specific for human mast cell tryptase. A one-way analysis of variance and Tukey's Honest Significance test was used to assess for statistical significance among and between the three groups. The average time from injury to the collection of the blood samples was 4 ± 2 days. Highly significant differences were identified between the operative, nonoperative, and control groups (P = .0005). In the operative group, SMCT levels were significantly higher than the nonoperative group (P = .0005) and the control group (P = .009), suggesting a correlation between SMCT levels and injury severity. There was no statistically significant difference in SMCT levels between the nonoperative and control groups. The SMCT levels were elevated in participants with acute elbow injuries requiring operative intervention, suggesting that SMCT levels were higher in injuries regarded as more severe.
Substances chimiques
Biomarkers
0
Tryptases
EC 3.4.21.59
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2015-2019Subventions
Organisme : CIHR
ID : 123790
Pays : Canada
Informations de copyright
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
Références
Sheehan SE, Dyer GS, Sodickson AD, Patel KI, Khurana B. Traumatic elbow injuries: what the orthopedic surgeon wants to know. Radiographics. 2013;33(3):869-888.
Lindenhovius AL, Jupiter JB. The posttraumatic stiff elbow: a review of the literature. J Hand Surg. 2007;32(10):1605-1623.
Schrumpf MA, Lyman S, Do H, et al. Incidence of postoperative elbow contracture release in New York state. J Hand Surg. 2013;38(9):1746-1752.e3.
Dickens JF, Wilson KW, Tintle SM, et al. Risk factors for decreased range of motion and poor outcomes in open periarticular elbow fractures. Injury. 2015;46(4):676-681.
Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA. The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm Res. 2012;61(4):285-292.
Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA. The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: A study of a rabbit model of posttraumatic joint contractures. J Bone Joint Surg Am. 2010;92(6):1468-1477.
Schneider P, Johal H, Zhang M, et al. 2016. The dose response effect of ketotifen fumarate on post traumatic joint contractures. Annual Meeting Paper No. 0221.
Kopka M, Monument MJ, Befus AD, et al. Serum mast cell tryptase as a marker of posttraumatic joint contracture in a rabbit model. J Orthop Trauma. 2017;31(3):e86-e89.
Metcalfe DD, Pawankar R, Ackerman SJ, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. WAOjournal. 2016;9(1):7.
Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316(26):1622-1626.
AO Foundation. 2009. Müller AO Classification of Fractures-Long Bones. www.aofoundation.org/Documents/mueller_ao_class.pdf
Edston E, van Hage-Hamsten M. Mast cell tryptase and hemolysis after trauma. Forensic Sci Int. 2003;131(1):8-13.
Gotlib J, Horny H, Valent P. Chapter 72: Mast cells and mastocytosis. Hematology. 7th ed. Philadelphia, PA: Elsevier Inc; 2018:1170-1186.
Beck SC, Wilding T, Buka RJ, Baretto RL, Huissoon AP, Krishna MT. Biomarkers in human anaphylaxis: a critical appraisal of current evidence and perspectives. Front Immunol. 2019;10:494.
Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551-1555.